Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to assess current practice patterns and barriers surrounding treatment with bispecific antibodies in appropriate patients with relapsed/refractory (R/R) FL in community oncology settings
Upon completion of this activity, participants should be better able to identify alignments and discordances in patient and provider perceptions about integrating novel bispecific antibodies for the treatment and management of R/R FL
Upon completion of this activity, participants should be better able to apply evidence-based guidelines to identify patients with R/R FL who would benefit from off-the-shelf bispecific antibody treatment modalities
Upon completion of this activity, participants should be better able to align clinical practice with expert recommendations for the management of adverse events associated with immunotherapies for R/R FL